JP2005524399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005524399A5 JP2005524399A5 JP2004501579A JP2004501579A JP2005524399A5 JP 2005524399 A5 JP2005524399 A5 JP 2005524399A5 JP 2004501579 A JP2004501579 A JP 2004501579A JP 2004501579 A JP2004501579 A JP 2004501579A JP 2005524399 A5 JP2005524399 A5 JP 2005524399A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer cells
- alcam
- pharmaceutical composition
- ability
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37747902P | 2002-05-03 | 2002-05-03 | |
| PCT/US2003/014025 WO2003093443A2 (en) | 2002-05-03 | 2003-05-02 | Alcam and alcam modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005524399A JP2005524399A (ja) | 2005-08-18 |
| JP2005524399A5 true JP2005524399A5 (https=) | 2006-03-16 |
Family
ID=29401505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501579A Withdrawn JP2005524399A (ja) | 2002-05-03 | 2003-05-02 | Ａｌｃａｍおよびａｌｃａｍ調節因子 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040048319A1 (https=) |
| EP (1) | EP1501544A4 (https=) |
| JP (1) | JP2005524399A (https=) |
| CN (1) | CN1662254A (https=) |
| AU (1) | AU2003225294A1 (https=) |
| CA (1) | CA2483912A1 (https=) |
| WO (1) | WO2003093443A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2565907A1 (en) * | 2004-05-17 | 2005-11-24 | Crucell Holland B.V. | Methods for diagnosis of acute myeloid leukemia |
| AU2006210589B2 (en) | 2005-02-02 | 2011-12-08 | Macrogenics West, Inc. | ADAM-9 modulators |
| WO2008063479A2 (en) * | 2006-11-17 | 2008-05-29 | Fred Hutchinson Cancer Research Center | Pancreatic cancer biomarkers |
| GB0705775D0 (en) * | 2007-03-26 | 2007-05-02 | Affitech As | Product |
| WO2008133945A1 (en) * | 2007-04-25 | 2008-11-06 | The Trustees Of The University Of Pennsylvania | Low level fluorescence detection at the light microscopic level |
| EP2065399A1 (en) * | 2007-11-30 | 2009-06-03 | Siemens Healthcare Diagnostics GmbH | The present invention relates to methods for prediction of the therapeutic success of breast cancer therapy |
| US20110151580A1 (en) * | 2007-11-06 | 2011-06-23 | University Health Network | Method for the detection of breast cancer by determining alcam and/or bcam levels in a patient |
| WO2009068423A2 (en) | 2007-11-30 | 2009-06-04 | Siemens Healthcare Diagnostics Gmbh | Method for predicting therapy responsiveness in basal like tumors |
| EP2376109B1 (en) | 2008-12-19 | 2019-01-23 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| SG168430A1 (en) * | 2009-07-22 | 2011-02-28 | Agency Science Tech & Res | Molecular signature of human lung cancer initiating cells |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| EP2601216B1 (en) | 2010-08-02 | 2018-01-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| KR101213445B1 (ko) | 2011-01-13 | 2012-12-18 | 강원대학교산학협력단 | 백혈구의 혈관외유출 억제 활성 및 암세포의 전이 억제 활성을 갖는 펩타이드를 포함하는 약학 조성물 |
| CA2836873C (en) | 2011-05-21 | 2019-10-22 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
| US9696312B2 (en) | 2011-09-02 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand |
| US10585102B2 (en) * | 2012-10-11 | 2020-03-10 | Vanderbilt University | Characterization of cancer using detection of activated leukocyte cell adhesion molecule (ALCAM) shedding |
| US10451628B2 (en) | 2014-05-07 | 2019-10-22 | University Of Utah Research Foundation | Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma |
| EP3152235B1 (en) | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| CN107849133B (zh) | 2015-05-04 | 2022-08-23 | 西托姆克斯治疗公司 | 抗cd166抗体、可活化抗cd166抗体及其使用方法 |
| EP3325006A4 (en) * | 2015-07-17 | 2019-03-06 | The Trustees of Columbia University in the City of New York | METHOD FOR TREATING CD166-EXPRESSIVE CANCER |
| WO2017019846A1 (en) | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
| US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| IL268836B2 (en) | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| MX2020000435A (es) | 2017-07-14 | 2020-08-17 | Cytomx Therapeutics Inc | Anticuerpos anti-cd166 y usos de estos. |
| SG11202005557TA (en) | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| SG11202007572VA (en) | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| US12415863B2 (en) | 2018-10-05 | 2025-09-16 | The Regents Of The University Of Michigan | Compositions and methods for treating cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| IE62463B1 (en) * | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
| US5552391A (en) * | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5846535A (en) * | 1990-10-12 | 1998-12-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for reducing tumor cell growth by using antibodies with broad tumor reactivity and limited normal tissue reactivity |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) * | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| AU669124B2 (en) * | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6210671B1 (en) * | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5998172A (en) * | 1993-11-02 | 1999-12-07 | Duke University | Anti-CD6 ligand antibodies |
| US5968768A (en) * | 1993-11-02 | 1999-10-19 | Duke University | CD6 ligand encoding sequence |
| CA2175247A1 (en) * | 1993-11-02 | 1995-05-11 | Barton F. Haynes | Cd6 ligand |
| US5532159A (en) * | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
| US6265150B1 (en) * | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| CA2282410A1 (en) * | 1997-03-03 | 1998-10-01 | Bristol-Myers Squibb Company | Monoclonal antibodies to human cd6 |
| AU9127098A (en) * | 1997-09-04 | 1999-03-22 | Osiris Therapeutics, Inc. | Ligands that modulate differentiation of mesenchymal stem cells |
| FR2796073B1 (fr) * | 1999-07-07 | 2003-08-29 | Centre Nat Rech Scient | Anticorps anti-idiotypiques des facteurs de croissance des fibroblastes et leur utilisation comme medicaments |
| US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
-
2003
- 2003-05-02 JP JP2004501579A patent/JP2005524399A/ja not_active Withdrawn
- 2003-05-02 US US10/428,983 patent/US20040048319A1/en not_active Abandoned
- 2003-05-02 AU AU2003225294A patent/AU2003225294A1/en not_active Abandoned
- 2003-05-02 WO PCT/US2003/014025 patent/WO2003093443A2/en not_active Ceased
- 2003-05-02 CA CA002483912A patent/CA2483912A1/en not_active Abandoned
- 2003-05-02 EP EP03722016A patent/EP1501544A4/en not_active Withdrawn
- 2003-05-02 CN CN038146886A patent/CN1662254A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005524399A5 (https=) | ||
| JP5109031B2 (ja) | 細胞結合性ｃａ１２５／ｏ７７２ｐに結合する抗体およびその使用方法 | |
| CN113924103B (zh) | 用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法 | |
| WO2021035188A1 (en) | Novel il-21 prodrugs and methods of use thereof | |
| Dohlsten et al. | Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. | |
| JP2019107018A5 (https=) | ||
| JP2008529497A5 (https=) | ||
| US9206240B2 (en) | Pseudomonas exotoxin A with less immunogenic B cell epitopes | |
| UA104130C2 (uk) | Антитіло, що специфічно зв'язується з il-4 і іl-13 та спосіб лікування астми у ссавця за допомогою такого антитіла | |
| JP2007504280A5 (https=) | ||
| JP2010508847A5 (https=) | ||
| IL184803A (en) | Purified antibodies against epha2, methods for their production, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating cancer | |
| JP2005505256A5 (https=) | ||
| JP2006514024A5 (https=) | ||
| TWI726217B (zh) | 含有抗globo h抗體之抗體－藥物共軛物及其用途 | |
| CN117482261A (zh) | 放射性免疫缀合物与检查点抑制剂组合疗法 | |
| WO2011137687A1 (zh) | 一种抗癌胚抗原抗体及其应用 | |
| CN102027014A (zh) | 用于治疗癌症的新抗体 | |
| EP4130046A1 (en) | Platform for constructing multispecific antibody | |
| JP2024512858A (ja) | 抗ｔｓｌｐナノ抗体およびその使用 | |
| CN119592592A (zh) | 用于用抗cd38免疫治疗来治疗癌症的组合物和方法 | |
| CN111825766B (zh) | 抗il-4r单域抗体及其应用 | |
| Zhu et al. | Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors | |
| CN117177999B (zh) | 一种靶向IL-18Rβ的抗体及其应用 | |
| CN110139661A (zh) | Igfb3及其受体相关疾病的治疗 |